## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `tirzepatide-glp1-agonists`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/tirzepatide-glp1-agonists/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tirzepatide-glp1-agonists/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/tirzepatide-glp1-agonists/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/tirzepatide-glp1-agonists/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/tirzepatide-glp1-agonists/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/tirzepatide-glp1-agonists/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `tirzepatide-glp1-agonists` v4 · content_hash `dcd6b7bdb3704e6e…` · thread_head genesis · 2 DIVs
- **thesis (c_map_tirzepatide-glp1-agonist):** Combinatorial mapping (transparent): tirzepatide vs glp1-agonists — regen=0.38, degen=0.35, Δ=0.03. Method: layer_relevance(0.75) × evidence_factor(0.40); catalog.degen_score for GLP-1 agonists (class).
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/tirzepatide-glp1-agonists/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/tirzepatide-glp1-agonists/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `tirzepatide-glp1-agonists`
- **title:** tirzepatide glp1 agonists
- **url:** https://miscsubjects.com/a/tirzepatide-glp1-agonists
- **register:** standard
- **updated:** 2026-07-17T02:43:16.096Z

## Body

## Overview
Evidence is being populated by Grok web search.

## Claims (1)

- **c_map_tirzepatide-glp1-agonist** [system w=0.35] Combinatorial mapping (transparent): tirzepatide vs glp1-agonists — regen=0.38, degen=0.35, Δ=0.03. Method: layer_relevance(0.75) × evidence_factor(0.40); catalog.degen_score for GLP-1 agonists (class).

## Voxel graph (1 atoms · 0 edges)
- full graph: https://miscsubjects.com/api/articles/tirzepatide-glp1-agonists/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (14)
- chain valid: yes · head: `8ba1f9ededee061d`

### s1 · pubmed · ok
- title: Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration
- url: https://pubmed.ncbi.nlm.nih.gov/40746703/
- summary: 2025 meta-analysis of 6 RCTs (6266 subjects) showing tirzepatide (5-15mg) superior for weight loss vs placebo/GLP-1 RAs; high-certainty for ≥15% loss.
- quote: A dose-dependent tirzepatide was superior to placebo and GLP-1 RAs in weight reduction. However, the lean mass reduction and tolerability require further investigation.
- hash: `0bc10e667490a0d1`

### s2 · pubmed · ok
- title: Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial
- url: https://pubmed.ncbi.nlm.nih.gov/42119587/
- summary: 2026 Lancet phase 3 trial on tirzepatide for weight maintenance in obesity.
- quote: We evaluated the efficacy and safety of continuing tirzepatide at the maximum tolerated dose (MTD) or lowering the dose to 5 mg compared with placebo.
- hash: `8f9696ced4d3722d`

### s3 · clinical_trial · ok
- title: Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes
- url: https://clinicaltrials.gov/study/NCT06820281
- summary: 2025 mechanistic trial on tirzepatide (GLP-1/GIP agonist) effects in type 1 diabetes.
- quote: This mechanistic study will define mechanisms by which GLP1-GIP co-agonism may uniquely provide clinical benefits in T1D during the fasting and fed states.
- hash: `167a284b48b25065`

### s4 · pubmed · ok
- title: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
- url: https://pubmed.ncbi.nlm.nih.gov/40353578/
- summary: 2025 SURMOUNT-5 trial: tirzepatide superior to semaglutide for weight loss in obesity without diabetes.
- quote: Among participants with obesity but without diabetes, treatment with tirzepatide was superior to treatment with semaglutide with respect to reduction in body weight.
- hash: `3fcae7a5d9dce8b0`

### s5 · pubmed · ok
- title: Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Clinical Trial
- url: https://pubmed.ncbi.nlm.nih.gov/41264593/
- summary: 2026 phase 2 trial showing tirzepatide benefits in T1D with obesity.
- quote: Among adults with type 1 diabetes and obesity, tirzepatide was superior to placebo for weight loss over 12 weeks.
- hash: `3d44a8cc318c688e`

### s6 · review · ok
- title: Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis
- url: https://pubmed.ncbi.nlm.nih.gov/41761267/
- summary: Systematic review and network meta-analysis of RCTs showing tirzepatide reduces MACE, CV mortality, all-cause mortality, non-fatal MI and stroke vs placebo, comparable to GLP-1RAs.
- quote: These findings suggest that tirzepatide provides cardiovascular benefit at least comparable to established GLP-1RAs, supporting its emerging role in cardiovascular risk reduction in T2D.
- hash: `8ee4366358b7274f`

### s7 · pubmed · ok
- title: Causes and consequences of discontinuation of GLP1RAs and tirzepatide
- url: https://pubmed.ncbi.nlm.nih.gov/42168641/
- summary: Review on discontinuation reasons for GLP-1RAs including tirzepatide and cardiometabolic evidence.
- quote: In this Review, we discuss common reasons for GLP1R agonist and tirzepatide discontinuation and examine available evidence related to potential cardiometabolic ...
- hash: `0371dcd0b18e6afd`

### s8 · pubmed · ok
- title: Ocular Outcomes with Tirzepatide versus Glucagon-like Peptide-1 Receptor Agonists
- url: https://pubmed.ncbi.nlm.nih.gov/41655764/
- summary: Study finding lower retinal complication risks with tirzepatide vs other GLP-1 RAs in T2D patients.
- quote: Among patients with T2D taking a GLP-1 RA, tirzepatide was associated with lower risks of retinal complications, need for vision-saving ...
- hash: `f48a6b4930245e0c`

### s9 · pubmed · ok
- title: Weight Loss With GLP-1 Agonists in Nondiabetic Adults
- url: https://pubmed.ncbi.nlm.nih.gov/41936548/
- summary: Analysis showing tirzepatide superior for weight loss in nondiabetic adults compared to other GLP-1 agonists.
- quote: Tirzepatide, particularly at higher doses, provides the greatest weight reduction in adults without diabetes.
- hash: `d7ea3b96d9412a96`

### s10 · pubmed · ok
- title: Tirzepatide for Obesity Treatment and Diabetes Prevention
- url: https://pubmed.ncbi.nlm.nih.gov/39536238/
- summary: Clinical trial on long-term tirzepatide effects for obesity and preventing diabetes.
- quote: Three years of treatment with tirzepatide in persons with obesity and prediabetes resulted in substantial and sustained weight reduction and a markedly ...
- hash: `618dbdfb4a58bbfe`

### s11 · pubmed · ok
- title: Real-world use and effectiveness of tirzepatide among ...
- url: https://pubmed.ncbi.nlm.nih.gov/39996368/
- summary: Real-world evidence on tirzepatide for weight loss in non-T2D patients.
- quote: To understand real-world tirzepatide utilization and effectiveness (change in weight and body mass index [BMI]) among people without type 2 diabetes (T2D) in ...
- hash: `90ba4559e112441e`

### s12 · pubmed · ok
- title: A real-world study of tirzepatide for weight loss in adults ...
- url: https://pubmed.ncbi.nlm.nih.gov/41354867/
- summary: Observational study on tirzepatide weight loss in obese non-diabetics.
- quote: In this prospective multicentre observational study, 115 adults with obesity but without diabetes were treated with tirzepatide 2.5 mg weekly for 4 weeks, ...
- hash: `f4c11038e72ab8c7`

### s13 · pubmed · ok
- title: Dose-Dependent Efficacy and Safety of Tirzepatide for ...
- url: https://pubmed.ncbi.nlm.nih.gov/40630338/
- summary: Meta-analysis of RCTs on dose-dependent effects in non-diabetic obesity.
- quote: Tirzepatide produces substantial, dose-dependent weight loss and improves metabolic and quality-of-life outcomes in obese adults without diabetes.
- hash: `aabf05417b19dead`

### s14 · pubmed · ok
- title: Insights into the Mechanism of Action of Tirzepatide
- url: https://pubmed.ncbi.nlm.nih.gov/41196501/
- summary: Narrative review on tirzepatide mechanisms as dual GIP/GLP-1 agonist.
- quote: Here, we review the mechanistic activity of tirzepatide and its effect on glycemic control, body weight, the cardiorenal system, and lipid metabolism.
- hash: `8ba1f9ededee061d`

## Provenance (5 model passes)
- chain valid: yes · head: `61f9753be67b3e00`

- populate-init · grok-4.3 · 2026-06-29T17:45 · hash `4b1319b76ff5`
- sources · grok-4.3 · 2026-06-29T17:45 · hash `4ec7f7717139`
- sources · grok-4.3 · 2026-06-29T17:45 · hash `1a8da71f439e`
- sources · grok-4.3 · 2026-06-29T17:46 · hash `febf2b2def38`
- voxel_divide · owner · 2026-07-17T02:43 · hash `61f9753be67b`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/tirzepatide-glp1-agonists/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/tirzepatide-glp1-agonists/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"tirzepatide-glp1-agonists","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest tirzepatide-glp1-agonists|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim tirzepatide-glp1-agonists|tier|assertion`
- **iMessage ask:** `tirzepatide-glp1-agonists|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `tirzepatide-glp1-agonists`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tirzepatide-glp1-agonists/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/tirzepatide-glp1-agonists/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*